Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial (vol 374, pg 796, 2009)

被引：0
|
作者：
Lennox, J. L.
Dejesus, E.
Lazzarin, A.
机构：
来源：
LANCET | 2009年 / 374卷 / 9692期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：786 / 786
页数：1
相关论文
共 50 条
  • [31] Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial
    Puls, Rebekah L.
    Amin, Janaki
    Losso, Marcelo
    Phanuphak, Praphan
    Nwizu, Chidi
    Orrell, Catherine
    Young, Barnaby
    Shahar, Eduardo
    Wolff, Marcelo
    Gazzard, Brian
    Read, Tim
    Hill, Andrew
    Cooper, David A.
    Emery, Sean
    LANCET, 2014, 383 (9927): : 1474 - 1482
  • [32] Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial
    Gallant, Joel
    Lazzarin, Adriano
    Mills, Anthony
    Orkin, Chloe
    Podzamczer, Daniel
    Tebas, Pablo
    Girard, Pierre-Marie
    Brar, Indira
    Daar, Eric S.
    Wohl, David
    Rockstroh, Juergen
    Wei, Xuelian
    Custodio, Joseph
    White, Kirsten
    Martin, Hal
    Cheng, Andrew
    Quirk, Erin
    LANCET, 2017, 390 (10107): : 2063 - 2072
  • [33] Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority study
    Molina, Jean-Michel
    LaMarca, Anthony
    Andrade-Villanueva, Jaime
    Clotet, Bonaventura
    Clumeck, Nathan
    Liu, Ya-Pei
    Zhong, Lijie
    Margot, Nicolas
    Cheng, Andrew K.
    Chuck, Steven L.
    LANCET INFECTIOUS DISEASES, 2012, 12 (01): : 27 - 35
  • [34] Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIA-ACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial (vol 374, pg 787, 2009)
    Sabatine, M. S.
    Antman, E. M.
    Widimsky, P.
    LANCET, 2009, 374 (9700): : 1502 - 1502
  • [35] Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial (vol 22, pg 209, 2023)
    Lipton, R. B.
    Croop, R.
    Stock, D. A.
    LANCET NEUROLOGY, 2023, 22 (05): : e7 - e7
  • [36] Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial
    Platzbecker, Uwe
    Wong, Raymond S. M.
    Verma, Amit
    Abboud, Camille
    Araujo, Sergio
    Chiou, Tzeon-Jye
    Feigert, John
    Yeh, Su-Peng
    Goetze, Katharina
    Gorin, Norbert-Claude
    Greenberg, Peter
    Kambhampati, Suman
    Kim, Yoo-Jin
    Lee, Je-Hwan
    Lyons, Roger
    Ruggeri, Marco
    Santini, Valeria
    Cheng, Gregory
    Jang, Jun Ho
    Chen, Chien-Yuan
    Johnson, Brendan
    Bennett, John
    Mannino, Frank
    Kamel, Yasser Mostafa
    Stone, Nicole
    Dougherty, Souria
    Chan, Geoffrey
    Giagounidis, Aristoteles
    LANCET HAEMATOLOGY, 2015, 2 (10): : E417 - E426
  • [37] Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naive adults with HIV-1 infection in the UK, based on the AIDS Clinical Trials Group 5202 clinical trial
    Wilkins, E.
    Fisher, M.
    Brogan, A. J.
    Talbird, S. E.
    La, E. M.
    HIV MEDICINE, 2016, 17 (07) : 505 - 515
  • [38] Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial
    Gallant, Joel E.
    Daar, Eric S.
    Raffi, Francois
    Brinson, Cynthia
    Ruane, Peter
    DeJesus, Edwin
    Johnson, Margaret
    Clumeck, Nathan
    Osiyemi, Olayemi
    Ward, Doug
    Morales-Ramirez, Javier
    Yan, Mingjin
    Abram, Michael E.
    Plummer, Andrew
    Cheng, Andrew K.
    Rhee, Martin S.
    LANCET HIV, 2016, 3 (04): : E158 - E165
  • [39] Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial
    Raffi, Francois
    Jaeger, Hans
    Quiros-Roldan, Eugenia
    Albrecht, Helmut
    Belonosova, Elena
    Gatell, Jose M.
    Baril, Jean-Guy
    Domingo, Pere
    Brennan, Care
    Almond, Steve
    Min, Sherene
    LANCET INFECTIOUS DISEASES, 2013, 13 (11): : 927 - 935
  • [40] Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks (vol 379, pg 2439, 2012)
    Sax, P. E.
    DeJesus, E.
    Mills, A.
    LANCET, 2012, 380 (9843): : 730 - 730
12345